- Home
- ONFO vs OGEN Comparison
ONFO vs OGEN Comparison
Compare ONFO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- OGEN
- Stock Information
- Founded
- ONFO 2018
- OGEN 1996
- Country
- ONFO United States
- OGEN United States
- Employees
- ONFO N/A
- OGEN N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- OGEN Health Care
- Exchange
- ONFO Nasdaq
- OGEN Nasdaq
- Market Cap
- ONFO 6.7M
- OGEN 5.5M
- IPO Year
- ONFO 2022
- OGEN N/A
- Fundamental
- Price
- ONFO $1.26
- OGEN $0.28
- Analyst Decision
- ONFO
- OGEN
- Analyst Count
- ONFO 0
- OGEN 0
- Target Price
- ONFO N/A
- OGEN N/A
- AVG Volume (30 Days)
- ONFO 158.2K
- OGEN 1.7M
- Earning Date
- ONFO 11-15-2024
- OGEN 11-13-2024
- Dividend Yield
- ONFO N/A
- OGEN N/A
- EPS Growth
- ONFO N/A
- OGEN N/A
- EPS
- ONFO N/A
- OGEN N/A
- Revenue
- ONFO $6,590,171.00
- OGEN N/A
- Revenue This Year
- ONFO $133.59
- OGEN N/A
- Revenue Next Year
- ONFO N/A
- OGEN N/A
- P/E Ratio
- ONFO N/A
- OGEN N/A
- Revenue Growth
- ONFO 29.25
- OGEN N/A
- 52 Week Low
- ONFO $0.39
- OGEN $0.25
- 52 Week High
- ONFO $1.88
- OGEN $6.22
- Technical
- Relative Strength Index (RSI)
- ONFO 44.75
- OGEN 38.94
- Support Level
- ONFO $1.15
- OGEN $0.34
- Resistance Level
- ONFO $1.39
- OGEN $0.42
- Average True Range (ATR)
- ONFO 0.09
- OGEN 0.05
- MACD
- ONFO -0.01
- OGEN -0.01
- Stochastic Oscillator
- ONFO 36.67
- OGEN 5.05
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.